AIDS (London, England) · 2025
Hepatitis B core antibody positivity is not associated with risk of transaminase elevation following switch to dual antiretroviral therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mezzadri Luca, Soria Alessandro Guido, Ranzani Alice, Malandrin Sergio, Sabbatini Francesca, Limonta Silvia, Cappelletti Anna, Colella Elisa, Squillace Nicola, Caramma Ilaria Chiara Giuseppina, Monti Bianca, Rugova Alban, Cavallero Annalisa, Bonfanti Paolo, Lapadula Giuseppe
Аннотация
OBJECTIVE: To evaluate whether hepatitis B core antibodies, indicative of possible occult hepatitis B virus (HBV) infection (pOBI), are associated with an increased risk of transaminase elevation in people with HIV (PWH) switching to two-drug regimens (2DR).
DESIGN: Cohort study.
METHODS: We included PWH who switched to 2DR since 2018, if they discontinued at least one anti-HBV drug and were HBsAg-negative at baseline. Two cohorts were analyzed: cohort 1 discontinued tenofovir (TFV) but continued lamivudine (3TC), Cohort 2 switched to regimens without HBV-active drugs. Survival analysis, including Cox regression adjusting for potential confounders, was conducted to compare time to grade ≥1 transaminase increase in those with and without pOBI.
RESULTS: Among 167 patients in cohort 1 (35.2% with pOBI), the rate of transaminitis was 4.59 vs. 7.47 per 100 person-years for those with and without pOBI [incidence rate ratio (IRR) 0.61; 95% confidence interval (CI) 0.17-1.83; P = 0.259]. Cox multivariable analysis found no significant association between pOBI and transaminitis (hazard ratio 0.56; 95% CI 0.2-1.5; P = 0.266), with adjusted models confirming these results. Among 118 individuals in cohort 2 (33.9% with pOBI), transaminitis rates were 8.04 vs. 8.68 per 100 person-years for those with and without pOBI (IRR 0.93; 95% CI 0.19-3.91; P = 0.763). Cox regression showed no significant association between pOBI and transaminitis (hazard ratio 1.18; 95% CI 0.4-3.6; P = 0.769), with consistent findings in adjusted models. No HBV reactivation occurred in either cohort.
CONCLUSION: pOBI was not associated with risk of transaminase elevation in PWH switching to dual therapies lacking anti-HBV agents.
DESIGN: Cohort study.
METHODS: We included PWH who switched to 2DR since 2018, if they discontinued at least one anti-HBV drug and were HBsAg-negative at baseline. Two cohorts were analyzed: cohort 1 discontinued tenofovir (TFV) but continued lamivudine (3TC), Cohort 2 switched to regimens without HBV-active drugs. Survival analysis, including Cox regression adjusting for potential confounders, was conducted to compare time to grade ≥1 transaminase increase in those with and without pOBI.
RESULTS: Among 167 patients in cohort 1 (35.2% with pOBI), the rate of transaminitis was 4.59 vs. 7.47 per 100 person-years for those with and without pOBI [incidence rate ratio (IRR) 0.61; 95% confidence interval (CI) 0.17-1.83; P = 0.259]. Cox multivariable analysis found no significant association between pOBI and transaminitis (hazard ratio 0.56; 95% CI 0.2-1.5; P = 0.266), with adjusted models confirming these results. Among 118 individuals in cohort 2 (33.9% with pOBI), transaminitis rates were 8.04 vs. 8.68 per 100 person-years for those with and without pOBI (IRR 0.93; 95% CI 0.19-3.91; P = 0.763). Cox regression showed no significant association between pOBI and transaminitis (hazard ratio 1.18; 95% CI 0.4-3.6; P = 0.769), with consistent findings in adjusted models. No HBV reactivation occurred in either cohort.
CONCLUSION: pOBI was not associated with risk of transaminase elevation in PWH switching to dual therapies lacking anti-HBV agents.